β-blockade in adriamycin-induced cardiomyopathy

Journal of Cardiac Failure

Volumn 6, Issue 2, 2000, Pages 115-119

  Noori, Arshia ^a   Lindenfeld, Joann ^a   Wolfel, Eugene ^a   Ferguson, Debbie ^a   Bristow, Michael R ^a   Lowes, Brian D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Adriamycin; Cardiomyopathy; blockade

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DOXORUBICIN; METOPROLOL; PROPRANOLOL;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOMYOPATHY; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033922894     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2000.7505     Document Type: Article

References (35)

1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14
2. Singal PK, Iliskovic N, Li T, Kumar D; Adriamycin cardiomyopathy: Pathophysiology and prevention. FASEB J 1997;11:931-6
3. Bristow MR, Monobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sageman WS, Daniels JR: Anthracycline-associated cardiac and renal damage in rabbits: Evidence for mediation by vasoactive substances. Lab Invest 1981;45:157-68
4. Singal PK, Deally CMR, Weinberg LE: Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol 1987;19:817-28
5. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983;43: 460-72
6. Singal PK, Siveski-Iliskovic N, Hill M, Thomas TP, Li T: Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 1995;27: 1055-63
7. Doroshow JH, Locker GY, Myers CE: Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J Clin Invest 1980; 65:128-35
8. Doroshow JH, Locker GY, Baldinger J. Myers CE: The effect of doxorubicin on hepatic and cardiac glutathione. Res Commun Chem Pathol Pharmacol 1979;26:285-95
9. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC: Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;197: 165-7
10. Thayer WS: Serum lipid peroxides in rats treated chronically with adriamycin. Biochem Pharmacol 1984;33: 2259-63
11. Lewis W, Gonzalez B: Actin isoform synthesis by cultured cardiac myocytes. Effects of doxorubicin. Lab Invest 1987; 56:295-301
12. Ito H, Miller S, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L, Torti FM: Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 1990;87:4275-9
13. Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, Snidow GH, Daniels JR: Acute and chronic cardiovascular effects of doxorubicin in the dog: The cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 1980;2:487-515
14. Bristow MR, Kantrowitz NE, Harrison WD, Minobe WA, Sageman WS, Billingham ME: Prevention of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharm 1983;5:913-9
15. Klugmann FB, Decorti G, Candussio L, Grill V, Mallardi F, Baldini L: Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo. Br J Cancer 1986;54:743-8
16. Minow RA, Benjamin RS, Lee ET, Gottlieb JA: Adriamycin cardiomyopathy-risk factors. Cancer 1977;39:1397-1402
17. Bristow MR: Anthracycline cardiotoxicity, in Bristow MR (ed): Drug-Induced Heart Disease. New York, NY, Elsevier, 1980, pp 191-215
18. Bristow MR, Mason JW, Billingham ME, Daniels JR: Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981;102:709-18
19. Van Acker SA, Kramer K, Voest EE, Grimbergen JA, Zhang J, van der Vijgh WJ, Bast A: Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. Cancer Chemother Pharmacol 1996;38:95-101
20. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC: Early anthracycline cardiotoxicity. Amer J Med 1978;65:823-32
21. Cohn JN: The management of chronic heart failure. N Engl J Med 1996;335:490-8
22. Shaddy RE, Olsen SL, Bristow MR, Taylor DO, Bullock EA, Tani LY, Renlund DG: Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 1995;129:197-9
23. Eiswirth CC, Bowden RE, Kazamias T, Fowler M, Bristow MR: Treatment of adriamycin cardiomyopathy with metoprolol. Circulation 1986;74(Suppl 2):310
24. Bristow MR: Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997;80(11A):26L-40L
25. CIBIS-II Investigators: The cardiac insufficiency bisoprolol study (CIBIS-II): a randomized trial. Lancet 1999;353: 9-13
26. Eichhorn EJ, Bristow MR: Medical therapy can improve the biologic properties of the chronically failing heart: A new era in the treatment of heart failure. Circulation 1996; 94:2285-96
27. Sinha BK, Chignell CF: Binding mode of chemically activated semiquinone free radicals from quinone anticancer agents to DNA. Chem Biol Interact 1979;28:301-8
28. Graves DE, Krugh TR: Adriamycin and daunorubicin bind in a cooperative manner to deoxyribonucleic acid. Biochemistry 1983;22:3941-7
29. Shapira J, Gotried M, Lishner M, Ravid M: Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. Cancer 1990;65:870-3
30. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ: Reducution of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Int Med 1982;96:133-9
31. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK: Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995;91: 10-15
32. Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW Jr, Billingham ME: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann Int Med 1983;99:745-9
33. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrens V, Stecy P, Zeleniuch-Jacquotte A: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319(12): 745-52
34. Freter CE, Lee TC, Billingham ME, Chak L, Bristow MR: Doxorubicin cardiac toxicity manifesting seven years after treatment. Amer J Med 1986;80:483-5
35. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7